Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are as follows:
To demonstrate the safety of escalating doses of opebacan in subjects undergoing
myeloablative allogeneic Hematopoietic Stem Cell Transplantation
To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic
Hematopoietic Stem Cell Transplantation
To determine if IV administration of opebacan is associated with changes in biological
markers for inflammation
To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem
Cell Transplantation related complications, including aGvHD